Oncimmune Holdings plc has placed and converted debt into equity
Oncimmune Holdings plc has raised US$2.9 million (£2.3 million) by placing and converting debt into equity to advance its pioneering work in autoantibody profiling and biomarker discovery, along with an additional US$4.1 million (€4 million) from debt conversion.
Oncimmune Holdings plc develops and commercializes technologies for cancer diagnosis in the UK, North America, Europe and beyond. The company offers EarlyCDT-Lung, a blood test for the early detection of lung cancer. Additionally, Oncimmune develops SeroTag, a platform for discovering and validating biomarkers to help stratify patients across multiple cancer indications, infectious diseases and autoimmune conditions. The company also offers NavigAID disease-specific stratification panels. Founded in 2015, Oncimmune is based in Nottingham, UK.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised Oncimmune Holdings plc on this transaction.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Backspin has completed a mandatory public tender offer for the shares of Spindox
Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.
Ver másRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Ver másLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Ver más